Actavis has reached attractive entry point, says Buckingham Buckingham believes that Actavis' generic business is surpassing expectations, and the firm raised its 2014 and 2015 EPS estimates for the company. The firm thinks the 9%+ retreat by the stock since late February has created an attractive entry point. It keeps a $275 price target and Buy rating on the shares.
News For ACT From The Last 14 Days
Check below for free stories on ACT the last two weeks.
Actavis files to sell 843,085 ordinary shares The offering is related to shares that may be issued upon the exercise of stock options granted under certain equity plans of Forest Laboratories to former employees or former directors of Forest.